Výsledky vyhledávání

Akademický článek

Baseline characteristics and treatment response predictive of nAMD outcomes with ranibizumab therapy in treatment-naive patients: the RACER subgroup analysis

Autor: Ching-Yao Tsai, Chien-Liang Wu, Cheng-Kuo Cheng, Yun-Dun Shen, Wen-Chuan Wu, Pei-Chang Wu, Arslan Tsai, Jiann-Torng Chen

Publikováno v: BMC Ophthalmology, Vol 23, Iss 1, Pp 1-11 (2023)

Abstract Background The Ranibizumab AMD Clinical Efficacy Study (RACER) conducted in treatment-naive adult Taiwanese patients with neovascular age-related macular degeneration (nAMD) suggested the importance of early and intensive dosing of ranibizum

Externí odkaz: https://doaj.org/article/86876a1393fa475cbc00ee759189466d

Zobrazit plný text záznamu

Akademický článek

Comparison of visual outcomes between therapy choices and subtypes of polypoidal choroidal vasculopathy (PCV) in Taiwan: a real-world study

Autor: Ling Yeung, Chi-Chun Lai, San-Ni Chen, Cheng-Kuo Cheng, Chung-May Yang, Yi-Ting Hsieh, Arslan Tsai, Chang-Hao Yang

Publikováno v: Scientific Reports, Vol 11, Iss 1, Pp 1-8 (2021)

Abstract Polypoidal choroidal vasculopathy (PCV) is a distinctive type of neovascular age-related macular degeneration prevalent in many Asian countries. However, there is still some controversy in how the subtypes of PCV are classified. This post-ho

Externí odkaz: https://doaj.org/article/e9d5bca02b8c40ecb7b9b5a7a841f401

Zobrazit plný text záznamu

Plný text ve formátu HTML

Comparison of visual outcomes between therapy choices and subtypes of polypoidal choroidal vasculopathy (PCV) in Taiwan: a real-world study

Autor: Cheng-Kuo Cheng, Yi-Ting Hsieh, Ling Yeung, Chung-May Yang, Arslan Tsai, Chang-Hao Yang, San-Ni Chen, Chi-Chun Lai

Publikováno v: Scientific Reports
Scientific Reports, Vol 11, Iss 1, Pp 1-8 (2021)

Polypoidal choroidal vasculopathy (PCV) is a distinctive type of neovascular age-related macular degeneration prevalent in many Asian countries. However, there is still some controversy in how the subtypes of PCV are classified. This post-hoc study r

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af3e36dd2445da04cd9e7fa605eb0785
https://doi.org/10.1038/s41598-020-80731-1

Zobrazit plný text záznamu

A 12-month, prospective, observational study of ranibizumab in treatment-naïve Taiwanese patients with neovascular age-related macular degeneration: the RACER study

Autor: Jiann-Torng Chen, Cheng-Kuo Cheng, Yun-Dun Shen, Wen-Chuan Wu, Arslan Tsai, Chien-Liang Wu, Ching-Yao Tsai, Pei-Chang Wu

Publikováno v: BMC Ophthalmology

Background The current National Health Insurance scheme in Taiwan reimburses 3 initial plus 4 additional injections of ranibizumab 0.5 mg for eligible patients with neovascular age-related macular degeneration (nAMD). The Ranibizumab AMD Clinical Eff

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dc9304e2033eeba6c5d1d425cb446b69
https://doi.org/10.1186/s12886-020-01715-3

Zobrazit plný text záznamu